Clinical Trial Search

Primary: Number of Lesions With a Change in Radiologist's Evaluation — 24 lesions

Primary: Number of Participants With Change in Radiologist's Lesion Evaluation — 0; 11; 0; 1 Participants

Primary: 3D CEUS Generated Metrics in Kidney Mass: Wash_In_Slope — 7.60 AU/second

Primary: Maximum Tolerated Dose of Radiosurgery — 48; 60 Gy

Primary: Response Rate — 1; 9.4; 12.6; 76.8 Percentage of participants

Primary: Response Rate — 8 Participants

Primary: Event-Free Survival of Patients With Diffuse Anaplastic Wilms' Tumor (DAWT) — 76.1; 25.0; 87.5 Percentage of 4-year OS — p=.0199

Primary: Successful Capture of IO-CEUS Images — 10 participants

Primary: Percentage of Participants' Best Overall Response Rate at 12 Months - Per Protocol Set (PP) — 0.0; 0.0; 56.7; 43.3 percentage of participants

Primary: Number of Participants With Presence of Fluorescence of cT1 RCC in Partial Nephrectomy Specimens — 10 Participants

Primary: Objective Response Rate — 44.4 percentage of participants

Primary: Progression-free Survival at 3 Months — 2.9 months

Primary: Objective Response Rate as Measured by RECIST Criteria After Every 2 Courses of Treatment for up to 6 Courses — 2 participants

Primary: Progression Free Survival (PFS) of Carfilzomib Therapy in Participants With Refractory Or Intolerant to Prior Therapy — 1.8 Months

Primary: PFS (Progression-Free Survival) — 27.71 Weeks

Primary: Overall Response Rate. — 3; 0; 75; 0 percentage of participants

Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants

Primary: Comparison in Radiologist's Lesion Evaluation: CEUS Versus B-mode Ultrasound — 0.13; 0.20 Dichotomized score

Primary: Percentage Change (From Baseline to 24 Hours) Between Metastatic and Benign Nodes — -33.6; -46.9 Percentage Change

Primary: Number of Patients With Ani-tumor Activity After Taking OSI-774. — 7 participants

Primary: Duration of Sunitinib and Pazopanib Treatment in Participants — 171; 114.5 days

Primary: Observed Response Rate — 0; 11 percentage of patients responding

Primary: Metabolic Response — 5 participants

Primary: Confirmed Response Rate (Complete Response and Partial Response) as Assessed by RECIST 1.1 Criteria — 14; 7; 4 Participants

Primary: Follow-up Duration — 1.07 years

Primary: Number of Participants According to Co-Diagnoses Before Index — 139; 45; 41; 26 Participants

Primary: Number of Patients With Adverse Events (AEs) — 3; 8; 3 Participants

Primary: Progression Free Survival (PFS) — 11 months

Primary: Progression Free Survival (PFS) — 5.6; 9.0; 2.8; 3.0 months — p=0.019

Primary: Response Rate by Solid Tumor Response Criteria (RECIST) — 16 Percentage of Participants